Gilead upgraded to Overweight from Equal Weight at Morgan …

6 days ago · Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for upward estimate revisions on lenacapavir forpre ...

$113
OFF

Gilead Upgraded To Overweight From Equal Weight At Morgan …

2 weeks from now

businessinsider.com

$113
OFF

Morgan Stanley Lifts Gilead Stock To Overweight On Lenacapavir ...

2 weeks from now

6 days ago · On Friday, Morgan Stanley (NYSE: MS) upgraded Gilead Sciences (NASDAQ: GILD)' stock rating from Equal-weight to Overweight and increased the price target to $113 …

investing.com

$113
OFF

Morgan Stanley Upgrades Gilead On HIV Treatment Growth

2 weeks from now

5 days ago · Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention …

yahoo.com

$113
OFF

Morgan Stanley Upgrades Gilead On HIV Treatment Growth

2 weeks from now

5 days ago · Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ: GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention …

investing.com

$113
OFF

Morgan Stanley Lifts Gilead Stock To Overweight On Lenacapavir ...

2 weeks from now

6 days ago · On Friday, Morgan Stanley (NYSE: MS) upgraded Gilead Sciences (NASDAQ: GILD)' stock rating from Equal-weight to Overweight and increased the price target to $113 …

investing.com

15%
OFF

Morgan Stanley Upgrades Gilead Sciences (LSE:0QYQ)

2 weeks from now

Dec 23, 2024 · Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences from Equal-Weight to Overweight.. Analyst Price Forecast Suggests 12.15% …

nasdaq.com

$113
OFF

Morgan Stanley Upgrades Gilead On HIV Treatment Growth Potential

2 weeks from now

5 days ago · Morgan Stanley has upgraded Gilead Sciences' stock to "overweight" from "equal weight," raising its price target to $113 from $87, citing the company's promising HIV treatment …

ainvest.com

$48
OFF

NNN REIT Upgraded To Overweight From Equal Weight At Morgan …

2 weeks from now

1 day ago · Morgan Stanley upgraded NNN REIT (NNN) to Overweight from Equal Weight with a $48 price target Tenant risk is expected to lead to muted growth in 2025, but this “may already …

businessinsider.com

43%
OFF

Morgan Stanley Upgrades Gilead Sciences (XTRA:GIS)

2 weeks from now

Dec 23, 2024 · Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences from Equal-Weight to Overweight.. Analyst Price Forecast Suggests 12.43% …

nasdaq.com

$37
OFF

Acuity Brands Upgraded To Overweight From Equal Weight At …

2 weeks from now

2 days ago · Morgan Stanley upgraded Acuity Brands to Overweight from Equal Weight with a price target of $37, down from $304.The firm says structurally higher growth and gross margin …

businessinsider.com

$105
OFF

Crown Holdings Upgraded To Overweight From Equal Weight At …

2 weeks from now

3 days ago · Morgan Stanley upgraded Crown Holdings to Overweight from Equal Weight with a price target of $105, down from $109.The firm believes the 2025 paper and packaging …

businessinsider.com

$530
OFF

RH Upgraded To Overweight From Equal Weight At Morgan Stanley

2 weeks from now

3 days ago · Morgan Stanley analyst Simeon Gutman upgraded RH (RH) to Overweight from Equal Weight with a price target of $530, up from $435. The firm says RH’s “stepped-up” …

businessinsider.com

FAQs about Gilead upgraded to Overweight from Equal Weight at Morgan … Coupon?

Why did Morgan Stanley upgrade Gilead Sciences (gild) to overweight?

Morgan Stanley has upgraded Gilead Sciences (NASDAQ: GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. ...

Is Gilead Sciences Inc (gild) overweight?

Related Articles Investing.com -- Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments. ...

Why did Morgan Stanley raise its price target for Gilead Sciences?

The bank raised its price target for the stock to $113 from $87. Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. ...

Is Gilead Sciences (Gild) a good stock to buy?

Morgan Stanley upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from an equal weight rating to an overweight rating in a research note published on Friday, MarketBeat.com reports. Morgan Stanley currently has $113.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $87.00. ...

Will Morgan Stanley upgrade Crown Holdings (CCK) to overweight?

Morgan Stanley upgraded Crown Holdings (CCK) to Overweight from Equal Weight with a price target of $105, down from $109. The firm believes the ... ...

Should you buy Gilead Sciences (Breen)?

Breen covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Amgen. According to TipRanks, Breen has an average return of -6.2% and a 33.33% success rate on recommended stocks. In addition to Bernstein, Gilead Sciences also received a Buy from Morgan Stanley’s Terence Flynn in a report issued yesterday. ...